EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Intranasal and inhaled delivery systems for targeting circadian dysfunction in neurodegenerative disorders, perspective and future outlook

Rhearne Ryan, Mathew N Leslie, Patrick He, Paul M Young, Camilla M Hoyos, Hui Xin Ong, Daniela Traini

Advanced Drug Delivery Reviews · 2025-05 · 220 · 115575

DOI: 10.1016/j.addr.2025.115575 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2025-05. Verfasst von Rhearne Ryan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Sleep and Chronobiology, The Woolcock Institute of Medical Research, Sydney, NSW 2113, Australia. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Drug Delivery Systems, Circadian Rhythm. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, National Heart Foundation of Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synchronisation of the suprachiasmatic nucleus (SCN) driven endogenous clock, located within the central nervous system (CNS), and exogenous time cues, is essential for maintaining circadian rhythmicity, homeostasis and overall wellbeing. Disordered circadian rhythms have been associated with various conditions, inclusive of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Traditional pharmacological approaches to circadian dysfunction in neurodegenerative disorders have primarily focused on oral drug delivery. Oral medications often face challenges in achieving the necessary systemic circulation to effectively bypass the blood brain barrier (BBB) and reach the CNS, primarily due to low or variable bioavailability. Advancements in non-invasive delivery methods, such as orally inhaled and intranasal formulations, present promising alternatives for targeting the CNS. Orally inhaled and intranasal drug delivery allows for medications to rapidly achieve high systemic circulation through increased bioavailability and fast onset of action. Additionally, intranasal delivery allows for therapies to bypass the BBB through the olfactory or trigeminal nerve pathways to directly enter the CNS. This review assesses the potential for orally inhaled and intranasal therapies to treat circadian disorders in neurodegenerative conditions. In addition, this review will explore melatonin as an example of enhancing therapeutic outcomes by adopting inhaled or intranasal drug delivery formulations to improve drug absorption and target circadian disorder more effectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurodegenerative DiseasesDrug Delivery SystemsCircadian RhythmHumansAdministration, IntranasalAnimalsAdministration, InhalationMelatonin

Stichwörter der Autor:innen

Circadian DisruptionCircadian RhythmDrug DeliveryInhaledIntranasalMelatoninNeurodegeneration

Substanzen

Melatonin

Autor:innen und Institutionen

  • Centre for Sleep and Chronobiology, The Woolcock Institute of Medical Research, Sydney, NSW 2113, Australia.
  • Respiratory Technology, The Woolcock Institute of Medical Research, Sydney, NSW 2113, Australia.
  • Respiratory Technology, The Woolcock Institute of Medical Research, Sydney, NSW 2113, Australia; Department of Marketing, Macquarie Business School, Macquarie University, Sydney, NSW 2109, Australia.
  • Centre for Sleep and Chronobiology, The Woolcock Institute of Medical Research, Sydney, NSW 2113, Australia; Department of Health Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, N…
  • Respiratory Technology, The Woolcock Institute of Medical Research, Sydney, NSW 2113, Australia; Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australi…

Förderung

  • National Health and Medical Research Council
  • National Heart Foundation of Australia

Zitieren

APA

Ryan, R., Leslie, M. N., He, P., Young, P. M., Hoyos, C. M., Ong, H. X., & Traini, D. (2025). Intranasal and inhaled delivery systems for targeting circadian dysfunction in neurodegenerative disorders, perspective and future outlook. Advanced Drug Delivery Reviews, 220, 115575. https://doi.org/10.1016/j.addr.2025.115575

Vancouver

Ryan R, Leslie MN, He P, Young PM, Hoyos CM, Ong HX, et al. Intranasal and inhaled delivery systems for targeting circadian dysfunction in neurodegenerative disorders, perspective and future outlook. Advanced Drug Delivery Reviews. 2025;220:115575. doi:10.1016/j.addr.2025.115575

BibTeX
@article{Ryan2025,
  author = {Ryan, Rhearne and Leslie, Mathew N and He, Patrick and Young, Paul M and Hoyos, Camilla M and Ong, Hui Xin and Traini, Daniela},
  title = {Intranasal and inhaled delivery systems for targeting circadian dysfunction in neurodegenerative disorders, perspective and future outlook},
  journal = {Advanced Drug Delivery Reviews},
  year = {2025},
  volume = {220},
  pages = {115575},
  doi = {10.1016/j.addr.2025.115575}
}
Kostenlos starten →